TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07629544: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Participants

Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 840 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07629544 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07629544 Rescue Dossier →